奧瑞利珠單抗
| 單株抗體 | |
|---|---|
| 種類 | 完整抗體 |
| 目標 | CD20 |
| 臨床資料 | |
| 商品名 | Ocrevus |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a617026 |
| 核准狀況 | |
| 懷孕分級 | |
| 給藥途徑 | 靜脈注射, 皮下注射 |
| ATC碼 | |
| 法律規範狀態 | |
| 法律規範 |
|
| 識別資訊 | |
| CAS號 | 637334-45-3  |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化學資訊 | |
| 化學式 | C6494H9978N1718O2014S46 |
| 摩爾質量 | 145,818.03 g·mol−1 |
奧瑞利珠單抗又譯為奧克萊珠單抗（INN：Ocrelizumab）用於治療多發性硬化症[10][11]。主要是針對復髮型（relapsing MS，RMS）和原發性進展型（primary progressive MS，PPMS)[11]。透過靜脈緩慢注射[11]。
常見副作用包括皮疹、瘙癢、呼吸困難和感染[11]。其他副作用包括可能癌症[10]。孕期使用的安全性不明[12]。它是一種單株抗體，可與B細胞上的CD20結合而減少其活性[11]。
奧瑞利珠單抗於2017年及2018年在美國及歐洲取得醫療使用許可[10] [11]。
參考文獻
[編輯]- ^ Ocrelizumab (Ocrevus) Use During Pregnancy. Drugs.com. 13 August 2019 [28 March 2020].
- ^ 2.0 2.1 Ocrevus PI (PDF). [31 March 2024].
- ^ Prescription medicines: registration of new chemical entities in Australia, 2017. Therapeutic Goods Administration (TGA). 21 June 2022 [9 April 2023].
- ^ Prescription medicines and biologicals: TGA annual summary 2017. Therapeutic Goods Administration (TGA). 21 June 2022 [31 March 2024].
- ^ Regulatory Decision Summary for Ocrevus. Drug and Health Product Register. 23 October 2014.
- ^ Neurological therapies. Health Canada. 9 May 2018 [13 April 2024].
- ^ Ocrevus 300 mg concentrate for solution for infusion - Summary of Product Characteristics (SmPC). (emc). 30 December 2019 [28 March 2020].
- ^ Ocrevus- ocrelizumab injection. DailyMed. 13 December 2019 [25 April 2020].
- ^ Ocrevus EPAR. European Medicines Agency (EMA). 11 January 2018 [25 April 2020].
本文含有此來源中屬於公有領域的內容。
- ^ 10.0 10.1 10.2 Ocrelizumab Monograph for Professionals. Drugs.com. [6 November 2021]. （原始內容存檔於17 March 2021） （英語）.
- ^ 11.0 11.1 11.2 11.3 11.4 11.5 Ocrevus EPAR. European Medicines Agency (EMA). [25 April 2020]. （原始內容存檔於27 March 2020）. 本文含有此來源中屬於公有領域的內容。
- ^ Ocrelizumab (Ocrevus) Use During Pregnancy. Drugs.com. [6 November 2021]. （原始內容存檔於28 March 2020） （英語）.
外部連結
[編輯]- Clinical trial number NCT01247324 for "A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis" at ClinicalTrials.gov
- Clinical trial number NCT01412333 for "A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis" at ClinicalTrials.gov
- Clinical trial number NCT01194570 for "A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis" at ClinicalTrials.gov
